-
1
-
-
44249106822
-
Health risks among travelers - Need for regular updates
-
DOI 10.1111/j.1708-8305.2008.00198.x
-
Steffen R, Amitirigala I, Mütsch M. Health risks among travellers - need for regular updates. J. Travel Med. 15(3), 145-146 (2008). (Pubitemid 351724956)
-
(2008)
Journal of Travel Medicine
, vol.15
, Issue.3
, pp. 145-146
-
-
Steffen, R.1
Amitirigala, I.2
Mutsch, M.3
-
2
-
-
0027174940
-
Hepatitis A and hepatitis B: Risks compared with other vaccine preventable diseases and immunization recommendations
-
DOI 10.1016/0264-410X(93)90221-I
-
Steffen R. Hepatitis A and B: risks compared with other vaccine-preventable diseases and immunization recommendations. Vaccine 11, 518-520 (1993). (Pubitemid 23130855)
-
(1993)
Vaccine
, vol.11
, Issue.5
, pp. 518-520
-
-
Steffen, R.1
-
3
-
-
70449715600
-
Hepatitis B immunization coverage and risk behaviour among danish travellers: Are immunization strategies based on single journey itineraries rational
-
Nielsen US, Petersen E, Larsen CS. Hepatitis B immunization coverage and risk behaviour among Danish travellers: are immunization strategies based on single journey itineraries rational? J. Infect. 59(5), 353-359 (2009).
-
(2009)
J. Infect.
, vol.59
, Issue.5
, pp. 353-359
-
-
Nielsen, U.S.1
Petersen, E.2
Larsen, C.S.3
-
4
-
-
33646715581
-
Prevention of hepatitis A through active or passive immunization: Recommendations of the advisory committee on immunization practices ACIP
-
CDC RR-7
-
CDC. Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm. Rep. 55(RR-7), 1-23 (2006).
-
(2006)
MMWR Recomm. Rep.
, vol.55
, pp. 1-23
-
-
-
5
-
-
0028928908
-
Clinical experience with an inactivated hepatitis A vaccine
-
Clemens R, Safary A, Hepburn A, Roche C, Stanbury WJ, André FE. Clinical experience with an inactivated hepatitis A vaccine. J. Infect. Dis. 171(Suppl. 1), S44-S49 (1995).
-
(1995)
J. Infect. Dis.
, vol.171
, Issue.1
-
-
Clemens, R.1
Safary, A.2
Hepburn, A.3
Roche, C.4
Stanbury, W.J.5
André, F.E.6
-
6
-
-
35548959176
-
Hepatitis A vaccine versus immune globulin for postexposure prophylaxis
-
DOI 10.1056/NEJMoa070546
-
Victor JC, Monto AS, Surdina TY et al. Hepatitis A vaccine versus immune globulin for postexposure prophylaxis. N. Engl. J. Med. 357(17), 1685-1694 (2007). (Pubitemid 350005150)
-
(2007)
New England Journal of Medicine
, vol.357
, Issue.17
, pp. 1685-1694
-
-
Victor, J.C.1
Monto, A.S.2
Surdina, T.Y.3
Suleimenova, S.Z.4
Vaughan, G.5
Nainan, O.V.6
Favorov, M.O.7
Margolis, H.S.8
Bell, B.P.9
-
7
-
-
35348976213
-
Update: Prevention of hepatitis A after exposure to hepatitis A virus and in international travelers updated recommendations of the advisory committee on immunization practices ACIP
-
CDC.
-
CDC. Update: prevention of hepatitis A after exposure to hepatitis A virus and in international travelers. Updated recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb. Mortal. Wkly Rep. 56(41), 1080-1084 (2007).
-
(2007)
MMWR Morb. Mortal. Wkly Rep.
, vol.56
, Issue.41
, pp. 1080-1084
-
-
-
8
-
-
67649297326
-
Surveillance for acute viral hepatitis - United States 2007
-
CDC.SS03
-
CDC. Surveillance for acute viral hepatitis - United States, 2007. MMWR Surveill. Summ. 58(SS03), 1-27 (2009).
-
(2009)
MMWR Surveill. Summ.
, Issue.58
, pp. 1-27
-
-
-
9
-
-
52649120886
-
Recommendations for identification and public health management of persons with chronic hepatitis B virus infection
-
RR-8
-
Weinbaum CM, Williams I, Mast EE et al. Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. MMWR Recomm. Rep. 57(RR-8), 1-28 (2008).
-
(2008)
MMWR Recomm. Rep.
, vol.57
, pp. 1-28
-
-
Weinbaum, C.M.1
Williams, I.2
Mast, E.E.3
-
10
-
-
39049191182
-
A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: Recommendations of the advisory committee on immunization practices ACIP part II: Immunization of adults
-
RR16
-
Mast EE, Weinbaum CM, Fiore AE et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP). Part II: Immunization of adults. MMWR Recomm. Rep. 55(RR16), 1-40 (2006).
-
(2006)
MMWR Recomm. Rep.
, vol.55
, pp. 1-40
-
-
Mast, E.E.1
Weinbaum, C.M.2
Fiore, A.E.3
-
11
-
-
79551617591
-
Recommended adult immunization schedule - United States 2011
-
CDC
-
CDC. Recommended adult immunization schedule - United States, 2011. MMWR Morb. Mortal. Wkly 60(4), 1-4 (2011).
-
(2011)
MMWR Morb. Mortal. Wkly
, vol.60
, Issue.4
, pp. 1-4
-
-
-
12
-
-
72849153267
-
Antibody levels and protection after hepatitis B vaccine: Results of a 22-year follow-up study and response to a booster dose
-
McMahon BJ, Dentinger CM, Bruden D et al. Antibody levels and protection after hepatitis B vaccine: results of a 22-year follow-up study and response to a booster dose. J. Infect. Dis. 200(9), 1390-1396 (2009).
-
(2009)
J. Infect. Dis.
, vol.200
, Issue.9
, pp. 1390-1396
-
-
McMahon, B.J.1
Dentinger, C.M.2
Bruden, D.3
-
13
-
-
0343090826
-
Can monovalent hepatitis A and B vaccines be replaced by a combined hepatitis A/B vaccine during the primary immunization course?
-
DOI 10.1016/S0264-410X(00)00166-3, PII S0264410X00001663
-
Kallinowski B, Knoll A, Lindner E et al. Can monovalent hepatitis A and B vaccines be replaced by a combined hepatitis A/B vaccine during the primary immunization course? Vaccine 19, 16-22 (2001). (Pubitemid 30618950)
-
(2000)
Vaccine
, vol.19
, Issue.1
, pp. 16-22
-
-
Kallinowski, B.1
Knoll, A.2
Lindner, E.3
Sanger, R.4
Stremmel, W.5
Vollmar, J.6
Zieger, B.7
Jilg, W.8
-
14
-
-
0345435056
-
The first combined vaccine against hepatitis A and B: An overview
-
DOI 10.1016/S0264-410X(98)00421-6, PII S0264410X98004216
-
Thoelen S, Van Damme P, Leentvaar- Kuypers A et al. The first combined vaccine against hepatitis A and B: an overview. Vaccine 17, 1657-1662 (1999). (Pubitemid 29138897)
-
(1999)
Vaccine
, vol.17
, Issue.13-14
, pp. 1657-1662
-
-
Thoelen, S.1
Van Damme, P.2
Leentvaar-Kuypers, A.3
Leroux-Roels, G.4
Bruguera, M.5
Frei, P.C.6
Bakasenas, V.7
Safary, A.8
-
15
-
-
0035929698
-
Notice to readers: FDA approval for a combined hepatitis A and B vaccine
-
CDC
-
CDC. Notice to readers: FDA approval for a combined hepatitis A and B vaccine. MMWR Morb. Mortal. Wkly Rep. 50, 806-807 (2001).
-
(2001)
MMWR Morb. Mortal. Wkly Rep.
, vol.50
, pp. 806-807
-
-
-
16
-
-
0034897845
-
Long-term persistence of antibodies induced by vaccination and safety follow-up with the first combined vaccine against hepatitis A and B in children and adults
-
Van Damme P, Leroux-Roels G, Law B et al. Long-term persistence of antibodies induced by vaccination and safety follow-up, with the first combined vaccine against hepatitis A and B in children and adults. J. Med. Virol. 65(1), 6-13 (2001).
-
(2001)
J. Med. Virol.
, vol.65
, Issue.1
, pp. 6-13
-
-
Van Damme, P.1
Leroux-Roels, G.2
Law, B.3
-
17
-
-
34247131249
-
Ten-year antibody persistence induced by hepatitis A and B vaccine (Twinrix™) in adults
-
DOI 10.1016/j.tmaid.2006.07.003, PII S1477893906000925
-
Van Herck K, Leroux-Roels G, Van Damme P, Srinivasa K, Hoet B. Ten-year antibody persistence induced by hepatitis A and B vaccine (Twinrix) in adults. Travel Med. Infect. Dis. 5(3), 171-175 (2007). (Pubitemid 46585955)
-
(2007)
Travel Medicine and Infectious Disease
, vol.5
, Issue.3
, pp. 171-175
-
-
Van Herck, K.1
Leroux-Roels, G.2
Van Damme, P.3
Srinivasa, K.4
Hoet, B.5
-
18
-
-
77955509544
-
Comparison of long-term 10 years immunogenicity of two-and three-dose regimens of a combined hepatitis A and B vaccine in adolescents
-
Beran J, Kervyn D, Wertzova V et al. Comparison of long-term (10 years) immunogenicity of two- and three-dose regimens of a combined hepatitis A and B vaccine in adolescents. Vaccine 28(37), 5993-5997 (2010).
-
(2010)
Vaccine
, vol.28
, Issue.37
, pp. 5993-5997
-
-
Beran, J.1
Kervyn, D.2
Wertzova, V.3
-
19
-
-
33846330603
-
Rapid and sustained immune response against hepatitis A and B achieved with combined vaccine using an accelerated administration schedule
-
DOI 10.1111/j.1708-8305.2006.00106.x
-
Connor BA, Blatter MM, Beran J, Zou B, Trofa AF. Rapid and sustained immune response against hepatitis A and B achieved with combined vaccine using an accelerated administration schedule. J. Travel Med. 14(1), 9-15 (2007). (Pubitemid 46114981)
-
(2007)
Journal of Travel Medicine
, vol.14
, Issue.1
, pp. 9-15
-
-
Connor, B.A.1
Blatter, M.M.2
Beran, J.3
Zou, B.4
Trofa, A.F.5
-
20
-
-
15244361739
-
A two-dose schedule for combined hepatitis A and B vaccination in children aged 6-15 years
-
DOI 10.1016/j.vaccine.2004.11.059
-
Kurugöl Z, Mutlubas F, Ozacar T. A two-dose schedule for combined hepatitis A and B vaccination in children aged 6-15 years. Vaccine 23(22), 2876-2880 (2005). (Pubitemid 40386489)
-
(2005)
Vaccine
, vol.23
, Issue.22
, pp. 2876-2880
-
-
Kurugol, Z.1
Mutlubas, F.2
Ozacar, T.3
-
21
-
-
20444367613
-
Immunogenicity of two paediatric doses of monovalent hepatitis B or combined hepatitis A and B vaccine in 8-10-year-old children
-
DOI 10.1016/j.vaccine.2004.07.022, PII S0264410X04005444
-
Duval B, Gilca V, Boulianne N, Deceuninck G, Rochette L, De Serres G. Immunogenicity of two paediatric doses ofmonovalent hepatitis B or combined hepatitis A and B vaccine in 8-10-year-old children. Vaccine 23(31), 4082-4087 (2005). (Pubitemid 40800670)
-
(2005)
Vaccine
, vol.23
, Issue.31
, pp. 4082-4087
-
-
Duval, B.1
Gilca, V.2
Boulianne, N.3
Deceuninck, G.4
Rochette, L.5
De Serres, G.6
-
22
-
-
40649093771
-
Long-term antibody persistence induced by a combined hepatitis A and B vaccine in children and adolescents
-
Diaz-Mitoma F, Law B, Subramanya A, Hoet B. Long-term antibody persistence induced by a combined hepatitis A and B vaccine in children and adolescents. Vaccine 26(14), 1759-1763 (2008).
-
(2008)
Vaccine
, vol.26
, Issue.14
, pp. 1759-1763
-
-
Diaz-Mitoma, F.1
Law, B.2
Subramanya, A.3
Hoet, B.4
-
23
-
-
30944452364
-
Combined typhoid fever and hepatitis A vaccine: Comparison of immunogenicity and safety to concomitant monovalent vaccine over 3 years
-
Overbosch D, Peyron F, Picot N et al. Combined typhoid fever and hepatitis A vaccine: comparison of immunogenicity and safety to concomitant monovalent vaccine over 3 years. J. Travel Med. 12(6), 319-326 (2005). (Pubitemid 43111736)
-
(2005)
Journal of Travel Medicine
, vol.12
, Issue.6
, pp. 319-326
-
-
Overbosch, D.1
Peyron, F.2
Picot, N.3
Varichon, J.-P.4
Dumas, R.5
Chambonneau, L.6
Weber, F.7
-
24
-
-
7444264760
-
Comparison of two combined vaccines against typhoid fever and hepatitis A in healthy adults
-
DOI 10.1016/j.vaccine.2004.05.040, PII S0264410X04006450
-
Beeching NJ, Clarke PD, Kitchin NR, Pirmohamed J, Veitch K, Weber F. Comparison of two combined vaccines against typhoid fever and hepatitis A in healthy adults. Vaccine 23(1), 29-35 (2004). (Pubitemid 39446356)
-
(2004)
Vaccine
, vol.23
, Issue.1
, pp. 29-35
-
-
Beeching, N.J.1
Clarke, P.D.2
E. Kitchin, N.R.3
Pirmohamed, J.4
Veitch, K.5
Weber, F.6
-
25
-
-
0142258054
-
A combined dual-chamber typhoid/hepatitis A vaccine as a booster dose in hepatitis A primed adults
-
DOI 10.1016/j.vaccine.2003.08.013
-
Beran J, Chlibek R, Weber F. A combined dual-chamber typhoid/hepatitis A vaccine as a booster dose in hepatitis A primed adults. Vaccine 21(32), 4650-4654 (2003). (Pubitemid 37329858)
-
(2003)
Vaccine
, vol.21
, Issue.32
, pp. 4650-4654
-
-
Beran, J.1
Chlibek, R.2
Weber, F.3
-
26
-
-
44349123571
-
Advisory committee on immunization practices centers for disease control and prevention CDC human rabies prevention - United States 2008: Recommendations of the advisory committee on immunization practices
-
RR-3
-
Manning SE, Rupprecht CE, Fishbein D et al.; Advisory Committee on Immunization Practices Centers for Disease Control and Prevention (CDC). Human rabies prevention - United States, 2008: recommendations of the Advisory Committee on Immunization Practices. MMWR Recomm. Rep. 57(RR-3), 1-28 (2008).
-
(2008)
MMWR Recomm. Rep.
, vol.57
, pp. 1-28
-
-
Manning, S.E.1
Rupprecht, C.E.2
Fishbein, D.3
-
27
-
-
77949896373
-
Centers for disease control and prevention CDC use of a reduced 4-dose vaccine schedule for postexposure prophylaxis to prevent human rabies: Recommendations of the advisory committee on immunization practices
-
RR-2
-
Rupprecht CE, Briggs D, Brown CM et al.; Centers for Disease Control and Prevention (CDC). Use of a reduced (4-dose) vaccine schedule for postexposure prophylaxis to prevent human rabies: recommendations of the Advisory Committee on Immunization Practices. MMWR Recomm. Rep. 59(RR-2), 1-9 (2010).
-
(2010)
MMWR Recomm. Rep.
, vol.59
, pp. 1-9
-
-
Rupprecht, C.E.1
Briggs, D.2
Brown, C.M.3
-
28
-
-
78751590009
-
Rabies vaccines: WHO position paper
-
WHO
-
WHO. Rabies vaccines: WHO position paper. Wkly Epidemiol. Rec. 85(32), 309-320 (2010).
-
(2010)
Wkly Epidemiol. Rec.
, vol.85
, Issue.32
, pp. 309-320
-
-
-
29
-
-
77956401638
-
Seroconversion following incomplete human rabies postexposure prophylaxis
-
Robertson K, Recuenco S, Niezgoda M, Garcia EJ, Rupprecht CE. Seroconversion following incomplete human rabies postexposure prophylaxis. Vaccine 28(39), 6523-6526 (2010).
-
(2010)
Vaccine
, vol.28
, Issue.39
, pp. 6523-6526
-
-
Robertson, K.1
Recuenco, S.2
Niezgoda, M.3
Garcia, E.J.4
Rupprecht, C.E.5
-
30
-
-
72049088299
-
Failure of rabies postexposure prophylaxis in patients presenting with unusual manifestations
-
Shantavasinkul P, Tantawichien T, Wacharapluesadee S et al. Failure of rabies postexposure prophylaxis in patients presenting with unusual manifestations. Clin. Infect. Dis. 50(1), 77-79 (2010).
-
(2010)
Clin. Infect. Dis.
, vol.50
, Issue.1
, pp. 77-79
-
-
Shantavasinkul, P.1
Tantawichien, T.2
Wacharapluesadee, S.3
-
31
-
-
33947132657
-
Animal-associated injuries and related diseases among returned travellers: A review of the GeoSentinel Surveillance Network
-
DOI 10.1016/j.vaccine.2006.12.034, PII S0264410X06013338
-
Gautret P, Schwartz E, Shaw M et al.; GeoSentinel Surveillance Network. Animal-associated injuries and related diseases among returned travellers: a review of the GeoSentinel Surveillance Network. Vaccine 25(14), 2656-2663 (2007). (Pubitemid 46400926)
-
(2007)
Vaccine
, vol.25
, Issue.14
, pp. 2656-2663
-
-
Gautret, P.1
Schwartz, E.2
Shaw, M.3
Soula, G.4
Gazin, P.5
Delmont, J.6
Parola, P.7
Soavi, M.J.8
Matchett, E.9
Brown, G.10
Torresi, J.11
-
32
-
-
13444282766
-
Influenza virus infection in travelers to tropical and subtropical countries
-
DOI 10.1086/429243
-
Mutsch M, Tavernini M, Marx A et al. Influenza virus infection in travelers to tropical and subtropical countries. Clin. Infect. Dis. 40, 1282-1287 (2005). (Pubitemid 40570237)
-
(2005)
Clinical Infectious Diseases
, vol.40
, Issue.9
, pp. 1282-1287
-
-
Mutsch, M.1
Tavernini, M.2
Marx, A.3
Gregory, V.4
Yi, P.L.5
Hay, A.J.6
Tschopp, A.7
Steffen, R.8
-
33
-
-
77955701149
-
Prevention and control of influenza with vaccines recommendations of the advisory committee on immunization practices ACIP 2010
-
CDC RR-8
-
CDC. Prevention and control of influenza with vaccines. Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Recomm. Rep. 59(RR-8), 1-68 (2010).
-
(2010)
MMWR Recomm. Rep.
, Issue.59
, pp. 1-68
-
-
-
34
-
-
77949702062
-
Japanese encephalitis vaccines: Recommendations of the advisory committee on immunization practices ACIP
-
CDC RR-1
-
CDC. Japanese encephalitis vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm. Rep. 59(RR-1), 1-27 (2010).
-
(2010)
MMWR Recomm. Rep.
, vol.59
, pp. 1-27
-
-
-
35
-
-
77952687751
-
Japanese encephalitis in travelers from non-endemic countries 1973-2008
-
Hills SI, Griggs AC, Fischer M. Japanese encephalitis in travelers from non-endemic countries, 1973-2008. Am. J. Trop. Med. Hyg. 82, 930-936 (2010).
-
(2010)
Am. J. Trop. Med. Hyg.
, vol.82
, pp. 930-936
-
-
Hills, S.I.1
Griggs, A.C.2
Fischer, M.3
-
36
-
-
79952672355
-
Japanese encephalitis in two children - United States 2010
-
CDC.
-
CDC. Japanese encephalitis in two children - United States, 2010. MMWR Morb. Mortal. Wkly Rep. 60(9), 276-278 (2011).
-
(2011)
MMWR Morb. Mortal. Wkly Rep.
, vol.60
, Issue.9
, pp. 276-278
-
-
-
37
-
-
67650581310
-
Japanese encephalitis among three US travelers returning from Asia 2003-2008
-
CDC.
-
CDC. Japanese encephalitis among three US travelers returning from Asia, 2003-2008. MMWR Morb. Mortal. Wkly Rep. 58(27), 737-740 (2009).
-
(2009)
MMWR Morb. Mortal. Wkly Rep.
, vol.58
, Issue.27
, pp. 737-740
-
-
-
38
-
-
61549095001
-
Comparison of a single high-dose vaccination regimen to the standard regimen for the investigational Japanese encephalitis vaccine IC51: A randomized observer-blind controlled phase 3 study
-
Schuller E, Klade CS, Wölfl G, Kaltenböck A, Dewasthaly S, Tauber E. Comparison of a single, high-dose vaccination regimen to the standard regimen for the investigational Japanese encephalitis vaccine, IC51: a randomized, observer-blind, controlled Phase 3 study. Vaccine 27(15), 2188-2193 (2009).
-
(2009)
Vaccine
, vol.27
, Issue.15
, pp. 2188-2193
-
-
Schuller, E.1
Klade, C.S.2
Wölfl, G.3
Kaltenböck, A.4
Dewasthaly, S.5
Tauber, E.6
-
39
-
-
47849106825
-
Long-term immunogenicity of the new vero cell-derived inactivated japanese encephalitis virus vaccine IC51: Six and 12 month results of a multicenter follow-up phase 3 study
-
Schuller E, Jilma B, Voicu V et al. Long-term immunogenicity of the new Vero cell-derived, inactivated Japanese encephalitis virus vaccine IC51: six and 12 month results of a multicenter follow-up Phase 3 study. Vaccine 26, 4382-4386 (2008).
-
(2008)
Vaccine
, vol.26
, pp. 4382-4386
-
-
Schuller, E.1
Jilma, B.2
Voicu, V.3
-
40
-
-
77954959942
-
Long-term immunity and immune response to a booster dose following vaccination with the inactivated Japanese encephalitis vaccine Ixiaro IC51
-
Dubischar-Kastner K, Eder S, Buerger V et al. Long-term immunity and immune response to a booster dose following vaccination with the inactivated Japanese encephalitis vaccine Ixiaro, IC51. Vaccine 28, 5197-5202 (2010).
-
(2010)
Vaccine
, vol.28
, pp. 5197-5202
-
-
Dubischar-Kastner, K.1
Eder, S.2
Buerger, V.3
-
41
-
-
84954358400
-
Effect of pre-existing anti-tick-borne encephalitis virus immunity on neutralising antibody response to the vero cell-derived inactivated Japanese encephalitis virus vaccine candidate IC51
-
Schuller E, Klade CS, Heinz FX et al. Effect of pre-existing anti-tick-borne encephalitis virus immunity on neutralising antibody response to the Vero cell-derived, inactivated Japanese encephalitis virus vaccine candidate IC51. Vaccine 26(48), 6151-6156 (2008).
-
(2008)
Vaccine
, vol.26
, Issue.48
, pp. 6151-6156
-
-
Schuller, E.1
Klade, C.S.2
Heinz, F.X.3
-
42
-
-
79952248906
-
Long term immunity following a booster dose of the inactivated Japanese encephalitis vaccine Ixiaro IC51
-
Eder S, Dubischar-Kastner K, Firbas C et al. Long term immunity following a booster dose of the inactivated Japanese encephalitis vaccine Ixiaro, IC51. Vaccine 29, 2607-2612 (2011).
-
(2011)
Vaccine
, vol.29
, pp. 2607-2612
-
-
Eder, S.1
Dubischar-Kastner, K.2
Firbas, C.3
-
43
-
-
79958287508
-
Recommendations for use of a booster dose of inactivated vero cell culture-derived Japanese encephalitis vaccine - Advisory committee on immunization practices 2011
-
CDC.
-
CDC. Recommendations for use of a booster dose of inactivated vero cell culture-derived Japanese encephalitis vaccine - Advisory Committee on Immunization Practices, 2011. MMWR Morb. Mortal. Wkly Rep. 60(20), 661-663 (2011).
-
(2011)
MMWR Morb. Mortal. Wkly Rep.
, vol.60
, Issue.20
, pp. 661-663
-
-
-
44
-
-
36549069631
-
Safety and immunogenicity of a Vero-cell-derived, inactivated Japanese encephalitis vaccine: A non-inferiority, phase III, randomised controlled trial
-
DOI 10.1016/S0140-6736(07)61780-2, PII S0140673607617802
-
Tauber E, Kollaritsch H, Korinek M et al. Safety and immunogenicity of a Vero-cellderived, inactivated Japanese encephalitis vaccine: a non-inferiority, Phase III, randomized controlled trial. Lancet 370, 1847-1853 (2007). (Pubitemid 350186053)
-
(2007)
Lancet
, vol.370
, Issue.9602
, pp. 1847-1853
-
-
Tauber, E.1
Kollaritsch, H.2
Korinek, M.3
Rendi-Wagner, P.4
Jilma, B.5
Firbas, C.6
Schranz, S.7
Jong, E.8
Klingler, A.9
Dewasthaly, S.10
Klade, C.11
-
45
-
-
71349087878
-
Immunogenicity and safety of IXIARO IC51 in a phase II study in healthy Indian children between 1 and 3 years of age
-
Kaltenbock A, Dubischar-Kastner K, Schuller E et al. Immunogenicity and safety of IXIARO (IC51) in a Phase II study in healthy Indian children between 1 and 3 years of age. Vaccine 28, 834-839 (2010).
-
(2010)
Vaccine
, vol.28
, pp. 834-839
-
-
Kaltenbock, A.1
Dubischar-Kastner, K.2
Schuller, E.3
-
46
-
-
85054108895
-
Safety immunogenicity and dose confirmation for the inactivated Japanese encephalitis vaccine IXIARO IC51 in filipino children aged 3 to 12 years
-
Boston MA USA
-
Dubischar-Kastner K, Kadlecek V, Sablan B et al. Safety, immunogenicity and dose confirmation for the inactivated Japanese encephalitis vaccine IXIARO, IC51, in Filipino children aged 3 to 12 years. Abstracts from the 12th Conference of International Society of Travel Medicine. Boston, MA, USA (2011).
-
(2011)
Abstracts from the 12th Conference of International Society of Travel Medicine
-
-
Dubischar-Kastner, K.1
Kadlecek, V.2
Sablan, B.3
-
47
-
-
79958249448
-
Update on Japanese encephalitis vaccine for children -United States may 2011
-
CDC
-
CDC. Update on Japanese encephalitis vaccine for children -United States, may 2011. MMWR Morb. Mortal. Wkly Rep. 60(20), 664-665 (2011).
-
(2011)
MMWR Morb. Mortal. Wkly Rep.
, vol.60
, Issue.20
, pp. 664-665
-
-
-
48
-
-
79954802756
-
The Global Meningococcal Initiative: Recommendations for reducing the global burden of meningococcal disease
-
Harrison LH, Pelton SI, Wilder-Smith A et al. The Global Meningococcal Initiative: recommendations for reducing the global burden of meningococcal disease. Vaccine 29(18), 3363-3371 (2011).
-
(2011)
Vaccine
, vol.29
, Issue.18
, pp. 3363-3371
-
-
Harrison, L.H.1
Pelton, S.I.2
Wilder-Smith, A.3
-
49
-
-
34548436899
-
Meningococcal vaccine in travelers
-
DOI 10.1097/QCO.0b013e3282a64700, PII 0000143220071000000003
-
Wilder-Smith A. Meningococcal vaccine in travelers. Curr. Opin. Infect. Dis. 20(5), 454-460 (2007). (Pubitemid 47359640)
-
(2007)
Current Opinion in Infectious Diseases
, vol.20
, Issue.5
, pp. 454-460
-
-
Wilder-Smith, A.1
-
50
-
-
0036066329
-
Where is the Meningitis Belt? Defining an area at risk of epidemic meningitis in Africa
-
DOI 10.1016/S0035-9203(02)90089-1
-
Molesworth AM, Thomson MC, Connor SJ et al. Where is the meningitis belt? Defining an area at risk of epidemic meningitis in Africa. Trans. R. Soc. Trop. Med. Hyg. 96, 242-249 (2002). (Pubitemid 34785056)
-
(2002)
Transactions of the Royal Society of Tropical Medicine and Hygiene
, vol.96
, Issue.3
, pp. 242-249
-
-
Molesworth, A.M.1
Thomson, M.C.2
Connor, S.J.3
Cresswell, M.P.4
Morse, A.P.5
Shears, P.6
Hart, C.A.7
Cuevas, L.E.8
-
51
-
-
0023724202
-
Group A meningococcal carriage in travelers returning from Saudi Arabia
-
Moore PS, Harrison LH, Telzak EE, Ajello GW, Broome CV. Group A meningococcal carriage in travelers returning from Saudi Arabia. JAMA 260(18), 1686-2689 (1988).
-
(1988)
JAMA
, vol.260
, Issue.18
, pp. 1686-2689
-
-
Moore, P.S.1
Harrison, L.H.2
Telzak, E.E.3
Ajello, G.W.4
Broome, C.V.5
-
52
-
-
0036133689
-
Meningococcal disease and travel
-
DOI 10.1086/323403
-
Memish ZA. Meningococcal disease and travel. Clin. Infect. Dis. 34, 84-90 (2002). (Pubitemid 33152671)
-
(2002)
Clinical Infectious Diseases
, vol.34
, Issue.1
, pp. 84-90
-
-
Memish, Z.A.1
-
53
-
-
26444518115
-
Safety, immunogenicity, and immune memory of a novel meningococcal (groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine (MCV-4) in healthy adolescents
-
DOI 10.1001/archpedi.159.10.907
-
Keyserling H, Papa T, Koranyi K et al. Safety, immunogenicity, and immune memory of a novel meningococcal (groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine (MCV-4) in healthy adolescents. Arch. Pediatr. Adolesc. Med. 159(10), 907-913 (2005). (Pubitemid 41423328)
-
(2005)
Archives of Pediatrics and Adolescent Medicine
, vol.159
, Issue.10
, pp. 907-913
-
-
Keyserling, H.1
Papa, T.2
Koranyi, K.3
Ryall, R.4
Bassily, E.5
Bybel, M.J.6
Sullivan, K.7
Gilmet, G.8
Reinhardt, A.9
-
54
-
-
70349560669
-
Updated recommendation from the advisory committee on immunization practices ACIP for revaccination of persons at prolonged increased risk for meningococcal disease
-
CDC
-
CDC. Updated recommendation from the Advisory Committee on Immunization Practices (ACIP) for revaccination of persons at prolonged increased risk for meningococcal disease. MMWR Morb. Mortal. Wkly Rep. 58(37), 1042-1043 (2009).
-
(2009)
MMWR Morb. Mortal. Wkly Rep.
, vol.58
, Issue.37
, pp. 1042-1043
-
-
-
55
-
-
63449126648
-
Immunogenicity and immune memory of a nonadjuvanted quadrivalent meningococcal glycoconjugate vaccine in infants
-
Perrett KP, Snape MD, Ford KJ et al. Immunogenicity and immune memory of a nonadjuvanted quadrivalent meningococcal glycoconjugate vaccine in infants. Pediatr. Infect. Dis. J. 28(3), 186-193 (2009).
-
(2009)
Pediatr. Infect. Dis. J.
, vol.28
, Issue.3
, pp. 186-193
-
-
Perrett, K.P.1
Snape, M.D.2
Ford, K.J.3
-
56
-
-
77949311018
-
Licensure of a meningococcal conjugate vaccine menveo and guidance for use - Advisory committee on immunization practices ACIP 2010
-
CDC.
-
CDC. Licensure of a meningococcal conjugate vaccine (Menveo) and guidance for use - Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Morb. Mortal. Wkly Rep. 59(9), 273 (2010).
-
(2010)
MMWR Morb. Mortal. Wkly Rep.
, vol.59
, Issue.9
, pp. 273
-
-
-
57
-
-
78650498911
-
Menveo®: A novel quadrivalent meningococcal CRM197 conjugate vaccine against serogroups A C W-135 and Y
-
Cooper B, DeTora L, Stoddard J. Menveo®: a novel quadrivalent meningococcal CRM197 conjugate vaccine against serogroups A, C, W-135 and Y. Expert Rev. Vaccines 10(1), 21-33 (2011).
-
(2011)
Expert Rev. Vaccines
, vol.10
, Issue.1
, pp. 21-33
-
-
Cooper, B.1
DeTora, L.2
Stoddard, J.3
-
58
-
-
79251607440
-
Updated recommendations for use of meningococcal conjugate vaccines - Advisory committee on immunization practices ACIP 2010
-
CDC.
-
CDC. Updated recommendations for use of meningococcal conjugate vaccines - Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Morb. Mortal. Wkly Rep. 60(3), 72-76 (2011).
-
(2011)
MMWR Morb. Mortal. Wkly Rep.
, vol.60
, Issue.3
, pp. 72-76
-
-
-
59
-
-
0035436653
-
Yellow fever: An update
-
DOI 10.1016/S1473-3099(01)00016-0, PII S1473309901000160
-
Monath TP. Yellow fever: an update. Lancet Infect. Dis. 1(1), 11-20 (2001). (Pubitemid 33586036)
-
(2001)
Lancet Infectious Diseases
, vol.1
, Issue.1
, pp. 11-20
-
-
Monath, T.P.1
-
60
-
-
79952206301
-
WHO yellow fever in Africa and central and south America 2008-2009
-
WHO. Yellow fever in Africa and Central and South America, 2008-2009. Wkly Epidemiol. Rec. 86(4), 25-36 (2011).
-
(2011)
Wkly Epidemiol. Rec.
, vol.86
, Issue.4
, pp. 25-36
-
-
-
61
-
-
85054106262
-
For the informal world health organization working group on geographic risk for yellow fever the revised global yellow fever risk map and recommendations for vaccination 2010: An international collaborative effort
-
In Press
-
Jentes ES, Poumerol G, Gershman MD et al. for the Informal World Health Organization Working Group on Geographic Risk for Yellow Fever. The revised global yellow fever risk map and recommendations for vaccination 2010: an international collaborative effort. Lancet Infect. Dis. (2011) (In Press).
-
(2011)
Lancet Infect. Dis.
-
-
Jentes, E.S.1
Poumerol, G.2
Gershman, M.D.3
-
62
-
-
0003987631
-
-
WHO 2nd Edition WHO Press.Geneva Switzerland
-
WHO. International Health Regulations (2nd Edition). WHO Press, Geneva, Switzerland (2005).
-
(2005)
International Health Regulations
-
-
-
63
-
-
0003864029
-
-
WHO WHO Press Geneva Switzerland
-
WHO. International Travel and Health. WHO Press, Geneva, Switzerland (2011).
-
(2011)
International Travel Health
-
-
-
64
-
-
40949091022
-
WHO outbreak news yellow fever Paraguay
-
WHO. Outbreak news. Yellow fever, Paraguay. Wkly Epidemiol. Rec. 83(12), 105 (2008).
-
(2008)
Wkly Epidemiol. Rec.
, vol.83
, Issue.12
, pp. 105
-
-
-
65
-
-
85159011903
-
Yellow fever vaccine
-
5th Edition Plotkin SA Orenstien WA Offit PA Eds Saunders PA USA
-
Monath TP, Cetron MS, Teuwen DE. Yellow fever vaccine. In: Vaccines (5th Edition). Plotkin SA, Orenstien WA, Offit PA (Eds). Saunders, PA, USA, 959-1055 (2008).
-
(2008)
Vaccines
, pp. 959-1055
-
-
Monath, T.P.1
Cetron, M.S.2
Teuwen, D.E.3
-
66
-
-
77955100138
-
Yellow fever vaccine: Recommendations of the advisory committee on immunization practices ACIP
-
RR-7
-
Staples JE, Gershman M, Fischer M. Yellow fever vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm. Rep. 59(RR-7), 1-27 (2010).
-
(2010)
MMWR Recomm. Rep.
, vol.59
, pp. 1-27
-
-
Staples, J.E.1
Gershman, M.2
Fischer, M.3
-
67
-
-
55249101442
-
Adverse event reports following yellow fever vaccination
-
Lindsey NP, Schroeder BA, Miller ER et al. Adverse event reports following yellow fever vaccination. Vaccine 26(48), 6077-6082 (2008).
-
(2008)
Vaccine
, vol.26
, Issue.48
, pp. 6077-6082
-
-
Lindsey, N.P.1
Schroeder, B.A.2
Miller, E.R.3
-
68
-
-
73949096411
-
Short report: Incidence of yellow fever vaccineassociated neurotropic disease
-
Guimard T, Minjolle S, Polard E et al. Short report: Incidence of yellow fever vaccineassociated neurotropic disease. Am. J. Trop. Med. Hyg. 81(6), 1141-1143 (2009).
-
(2009)
Am. J. Trop. Med. Hyg.
, vol.81
, Issue.6
, pp. 1141-1143
-
-
Guimard, T.1
Minjolle, S.2
Polard, E.3
-
69
-
-
33846674490
-
Neurologic disease associated with 17D-204 yellow fever vaccination: A report of 15 cases
-
DOI 10.1016/j.vaccine.2006.11.027, PII S0264410X06012291
-
McMahon AW, Barwick Eidex R, Marfin AA et al. Neurologic disease associated with 17D-204 yellow fever vaccination: a report of 15 cases. Vaccine 25(10), 1727-1734 (2007). (Pubitemid 46188373)
-
(2007)
Vaccine
, vol.25
, Issue.10
, pp. 1727-1734
-
-
McMahon, A.W.1
Eidex, R.B.2
Marfin, A.A.3
Russell, M.4
Sejvar, J.J.5
Markoff, L.6
Hayes, E.B.7
Chen, R.T.8
Ball, R.9
Braun, M.M.10
Cetron, M.11
-
70
-
-
70349435917
-
Viscerotropic disease following yellow fever vaccination in Peru
-
Whittembury A, Ramirez G, Hernandez H et al. Viscerotropic disease following yellow fever vaccination in Peru. Vaccine 27(43), 5974-5981 (2009).
-
(2009)
Vaccine
, vol.27
, Issue.43
, pp. 5974-5981
-
-
Whittembury, A.1
Ramirez, G.2
Hernandez, H.3
-
71
-
-
74549202279
-
Clinical and immunological insights on severe adverse neurotropic and viscerotropic disease following 17D yellow fever vaccination
-
Silva ML, Espirito-Santo LR, Martins MA et al. Clinical and immunological insights on severe, adverse neurotropic and viscerotropic disease following 17D yellow fever vaccination. Clin. Vaccine Immunol. 17(1), 118-126 (2010).
-
(2010)
Clin. Vaccine Immunol.
, vol.17
, Issue.1
, pp. 118-126
-
-
Silva, M.L.1
Espirito-Santo, L.R.2
Martins, M.A.3
-
73
-
-
48749110535
-
Case of yellow fever vaccine-associated viscerotropic disease with prolonged viremia, robust adaptive immune responses and polymorphisms in CCR5 and RANTES genes
-
Pulendran B, Miller J, Querec TD et al. Case of yellow fever vaccine-associated viscerotropic disease with prolonged viremia, robust adaptive immune responses, and polymorphisms in CCR5 and RANTES genes. J. Infect. Dis. 198(4), 500-507 (2008).
-
(2008)
J. Infect. Dis.
, vol.198
, Issue.4
, pp. 500-507
-
-
Pulendran, B.1
Miller, J.2
Querec, T.D.3
-
74
-
-
59649129816
-
Yellow fever vaccine induces integrated multilineage and polyfunctional immune responses
-
Gaucher D, Therrien R, Kettaf N et al. Yellow fever vaccine induces integrated multilineage and polyfunctional immune responses. J. Exp. Med. 205(13), 3119-3131 (2008).
-
(2008)
J. Exp. Med.
, vol.205
, Issue.13
, pp. 3119-3131
-
-
Gaucher, D.1
Therrien, R.2
Kettaf, N.3
-
75
-
-
36249021519
-
Fatal multiorgan failure due to yellow fever vaccine-associated viscerotropic disease
-
DOI 10.1016/j.vaccine.2007.08.061, PII S0264410X07009814
-
Belsher JL, Gay P, Brinton M et al. Fatal multiorgan failure due to yellow fever vaccine-associated viscerotropic disease. Vaccine 25(50), 8480-8485 (2007). (Pubitemid 350137593)
-
(2007)
Vaccine
, vol.25
, Issue.50
, pp. 8480-8485
-
-
Belsher, J.L.1
Gay, P.2
Brinton, M.3
DellaValla, J.4
Ridenour, R.5
Lanciotti, R.6
Perelygin, A.7
Zaki, S.8
Paddock, C.9
Querec, T.10
Zhu, T.11
Pulendran, B.12
Eidex, R.B.13
Hayes, E.14
-
76
-
-
4444359788
-
For the yellow fever vaccine safety working group history of thymoma and yellow fever vaccination letter
-
Barwick Eidex R, for the Yellow Fever Vaccine Safety Working Group. History of thymoma and yellow fever vaccination (letter). Lancet 364(9438), 936 (2004).
-
(2004)
Lancet
, vol.364
, Issue.9438
, pp. 936
-
-
Barwick Eidex, R.1
-
77
-
-
79952319151
-
Case report: Probable transmission of vaccine strain of yellow fever virus to an infant via breast milk
-
Kuhn S, Twele-Montecinos L, Macdonald J, Webster P, Law B. Case report: probable transmission of vaccine strain of yellow fever virus to an infant via breast milk. CMAJ 183(4), E243-E245 (2011).
-
(2011)
CMAJ
, vol.183
, Issue.4
-
-
Kuhn, S.1
Twele-Montecinos, L.2
Macdonald, J.3
Webster, P.4
Law, B.5
-
78
-
-
77649220044
-
WHO global advisory committee on vaccine safety
-
3-4 December 2009.
-
WHO. Global Advisory Committee on Vaccine Safety, 3-4 December 2009. Wkly Epidemiol. Rec. 85(5), 29-33 (2010).
-
(2010)
Wkly Epidemiol. Rec.
, vol.85
, Issue.5
, pp. 29-33
-
-
-
79
-
-
76749123835
-
Transmission of yellow fever vaccine virus through breast-feeding - Brazil 2009
-
CDC.
-
CDC. Transmission of yellow fever vaccine virus through breast-feeding - Brazil, 2009. MMWR Morb. Mortal. Wkly Rep. 59(5), 130-132 (2010).
-
(2010)
MMWR Morb. Mortal. Wkly Rep.
, vol.59
, Issue.5
, pp. 130-132
-
-
-
80
-
-
32344446559
-
The effects of yellow fever immunization (17DD) inadvertently used in early pregnancy during a mass campaign in Brazil
-
DOI 10.1016/j.vaccine.2005.09.033, PII S0264410X0500976X
-
Suzano CE, Amaral E, Sato HK, Papaiordanou PM. The effects of yellow fever immunization (17DD) inadvertently used in early pregnancy during a mass campaign in Brazil. Vaccine 24(6), 1421-1426 (2006). (Pubitemid 43222053)
-
(2006)
Vaccine
, vol.24
, Issue.9
, pp. 1421-1426
-
-
Suzano, C.E.S.1
Amaral, E.2
Sato, H.K.3
Papaiordanou, P.M.4
Marba, S.5
Pessoto, M.6
Cavalcanti, D.7
Altemani, A.8
Cecatti, J.G.9
Freire, M.10
Gouveia, M.F.11
Suzuki, A.12
-
81
-
-
0345337263
-
Exposure to yellow fever vaccine in early pregnancy
-
DOI 10.1016/S0264-410X(98)00051-6, PII S0264410X98000516
-
Robert E, Vial T, Schaefer C, Arnon J, Reuvers M. Exposure to yellow fever vaccine in early pregnancy. Vaccine 17, 283-285 (1999). (Pubitemid 28552788)
-
(1999)
Vaccine
, vol.17
, Issue.3
, pp. 283-285
-
-
Robert, E.1
Vial, T.2
Schaefer, C.3
Arnon, J.4
Reuvers, M.5
-
82
-
-
0027362762
-
Congenital yellow fever virus infection after immunization in pregnancy
-
Tsai TF, Paul R, Lynberg MC, Letson GW. Congenital yellow fever virus infection after immunization in pregnancy. J. Infect. Dis. 168, 1520-1523 (1993). (Pubitemid 23344916)
-
(1993)
Journal of Infectious Diseases
, vol.168
, Issue.6
, pp. 1520-1523
-
-
Tsai, T.F.1
Paul, R.2
Lynberg, M.C.3
Letson, G.W.4
-
83
-
-
0027234707
-
Yellow fever vaccination and pregnancy: A four-year prospective study
-
Nasidi A, Monath TP, Vandenberg J et al. Yellow fever vaccination and pregnancy: a four-year prospective study. Trans. R. Soc. Trop. Med. Hyg. 87, 337-339 (1993).
-
(1993)
Trans. R. Soc. Trop. Med. Hyg.
, vol.87
, pp. 337-339
-
-
Nasidi, A.1
Monath, T.P.2
Vandenberg, J.3
-
84
-
-
60549101423
-
Immunogenicity and safety of yellow fever vaccination for 102 HIV-infected patients
-
Veit O, Niedrig M, Chapuis-Taillard C et al. Immunogenicity and safety of yellow fever vaccination for 102 HIV-infected patients. Clin. Infect. Dis. 48(5), 659-666 (2009).
-
(2009)
Clin. Infect. Dis.
, vol.48
, Issue.5
, pp. 659-666
-
-
Veit, O.1
Niedrig, M.2
Chapuis-Taillard, C.3
-
85
-
-
79958836540
-
WHO vaccines against tick-borne encephalitis: WHO position paper
-
WHO. Vaccines against tick-borne encephalitis: WHO position paper. Wkly Epidemiol. Rec. 86(24), 241-256 (2011).
-
(2011)
Wkly Epidemiol. Rec.
, vol.86
, Issue.24
, pp. 241-256
-
-
-
86
-
-
77949982454
-
CDC tick-borne encephalitis among US travelers to europe and Asia - 2000-2009
-
CDC. Tick-borne encephalitis among U.S. travelers to Europe and Asia - 2000-2009. MMWR Morb. Mortal. Wkly Rep. 59(11), 335-338 (2010).
-
(2010)
MMWR Morb. Mortal. Wkly Rep.
, vol.59
, Issue.11
, pp. 335-338
-
-
-
87
-
-
33846204617
-
Tick-borne encephalitis TBE vaccination: Applying the most suitable vaccination schedule
-
Schöndorf I, Beran J, Cizkova D, Lesna V, Banzhoff A, Zent O. Tick-borne encephalitis (TBE) vaccination: applying the most suitable vaccination schedule. Vaccine 25, 1470-1476 (2007).
-
(2007)
Vaccine
, vol.25
, pp. 1470-1476
-
-
Schöndorf, I.1
Beran, J.2
Cizkova, D.3
Lesna, V.4
Banzhoff, A.5
Zent, O.6
-
88
-
-
33947704636
-
Tick-borne encephalitis (TBE) vaccination in children: Advantage of the rapid immunization schedule (i.e., days O, 7, 21)
-
Schoendorf I, Ternak G, Oroszlàn G, Nicolay U, Banzhoff A, Zent O. Tick-borne encephalitis (TBE) vaccination in children: advantage of the rapid immunization schedule (i.e., days 0, 7, 21). Hum. Vaccines 2, 42-47 (2007). (Pubitemid 46493604)
-
(2007)
Human Vaccines
, vol.3
, Issue.2
, pp. 42-47
-
-
Schoendorf, I.1
Ternak, G.2
Oroszlan, G.3
Nicolay, U.4
Banzhoff, A.5
Zent, O.6
-
90
-
-
79961085080
-
-
WHO Cholera 2010
-
WHO. Cholera, 2010. Wkly Epidemiol. Rec. 86(31), 325-339 (2011).
-
(2011)
Wkly Epidemiol. Rec.
, vol.86
, Issue.31
, pp. 325-339
-
-
-
91
-
-
78649874927
-
A national cholera vaccine stockpile - A new humanitarian and diplomatic resource
-
Waldor MK, Hotez PJ, Clemens JD. A national cholera vaccine stockpile - a new humanitarian and diplomatic resource. N. Engl. J. Med. 363(24), 2279-2282 (2010).
-
(2010)
N. Engl. J. Med.
, vol.363
, Issue.24
, pp. 2279-2282
-
-
Waldor, M.K.1
Hotez, P.J.2
Clemens, J.D.3
-
92
-
-
79957448582
-
Oral vaccines against cholera
-
Shin S, Desai SN, Sah BK, Clemens JD. Oral vaccines against cholera. Clin. Infect. Dis. 52(11), 1343-1349 (2011).
-
(2011)
Clin. Infect. Dis.
, vol.52
, Issue.11
, pp. 1343-1349
-
-
Shin, S.1
Desai, S.N.2
Sah, B.K.3
Clemens, J.D.4
-
93
-
-
33646682630
-
Oral cholera vaccines: Use in clinical practice
-
DOI 10.1016/S1473-3099(06)70494-7, PII S1473309906704947
-
Hill DR, Ford L, Lalloo DG. Oral cholera vaccines: use in clinical practice. Lancet Infect. Dis. 6, 361-373 (2006). (Pubitemid 43737274)
-
(2006)
Lancet Infectious Diseases
, vol.6
, Issue.6
, pp. 361-373
-
-
Hill, D.R.1
Ford, L.2
Lalloo, D.G.3
-
94
-
-
58449133479
-
Cost-benefit of WC/rBS oral cholera vaccine for vaccination against ETEC-caused travelers diarrhea
-
Lundkvist J, Steffen R, Jönsson B. Cost-benefit of WC/rBS oral cholera vaccine for vaccination against ETEC-caused travelers' diarrhea. J. Travel Med. 16(1), 28-34 (2009).
-
(2009)
J. Travel Med.
, vol.16
, Issue.1
, pp. 28-34
-
-
Lundkvist, J.1
Steffen, R.2
Jönsson, B.3
-
95
-
-
55049084757
-
Geographic expansion of dengue: The impact of international travel
-
x
-
Wilder-Smith A, Gubler DJ. Geographic expansion of dengue: the impact of international travel. Med. Clin. North. Am. 92(6), 1377-1390, x (2008).
-
(2008)
Med. Clin. North. Am.
, vol.92
, Issue.6
, pp. 1377-1390
-
-
Wilder-Smith, A.1
Gubler, D.J.2
-
96
-
-
80053984779
-
Update on dengue: Epidemiology virus evolution antiviral drugs and vaccine development
-
Wilder-Smith A, Ooi EE, Vasudevan SG, Gubler DJ. Update on dengue: epidemiology, virus evolution, antiviral drugs, and vaccine development. Curr. Infect. Dis. Rep. 12(3), 157-164 (2010).
-
(2010)
Curr. Infect. Dis. Rep.
, vol.12
, Issue.3
, pp. 157-164
-
-
Wilder-Smith, A.1
Ooi, E.E.2
Vasudevan, S.G.3
Gubler, D.J.4
-
98
-
-
45849141443
-
Seasonality, annual trends, and characteristics of dengue among Ill returned travelers, 1997-2006
-
DOI 10.3201/eid1407.071412
-
Schwartz E, Weld LH, Wilder-Smith A et al. Seasonality, annual trends, and characteristics of dengue among ill returned travelers, 1997-2006. Emerg. Infect. Dis. 14(7), 1081-1088 (2008). (Pubitemid 351920438)
-
(2008)
Emerging Infectious Diseases
, vol.14
, Issue.7
, pp. 1081-1088
-
-
Schwartz, E.1
Weld, L.H.2
Wilder-Smith, A.3
Von Sonnenburg, F.4
Keystone, J.S.5
Kain, K.C.6
Torresi, J.7
Freedman, D.O.8
-
99
-
-
30444453688
-
Spectrum of disease and relation to place of exposure among ill returned travelers
-
DOI 10.1056/NEJMoa051331
-
Freedman DO, Weld LH, Kozarsky PE et al. Spectrum of disease and relation to place of exposure among ill returned travelers. N. Engl. J. Med. 354(2), 119-130 (2006). (Pubitemid 43076709)
-
(2006)
New England Journal of Medicine
, vol.354
, Issue.2
, pp. 119-130
-
-
Freedman, D.O.1
Weld, L.H.2
Kozarsky, P.E.3
Fisk, T.4
Robins, R.5
Von Sonnenburg, F.6
Keystone, J.S.7
Pandey, P.8
Cetron, M.S.9
-
100
-
-
45849101684
-
Dengue vaccines for travelers
-
DOI 10.1586/14760584.7.5.569
-
Wilder-Smith A, Deen JL. Dengue vaccines for travelers. Expert Rev. Vaccines 7(5), 569-578 (2008). (Pubitemid 351881341)
-
(2008)
Expert Review of Vaccines
, vol.7
, Issue.5
, pp. 569-578
-
-
Wilder-Smith, A.1
Deen, J.L.2
-
101
-
-
36549054066
-
Dengue and yellow fever - Challenges for the development and use of vaccines
-
DOI 10.1056/NEJMp0707161
-
Monath TP. Dengue and yellow fever - challenges for the development and use of vaccines. N. Engl. J. Med. 357(22), 2222-2225 (2007). (Pubitemid 350190752)
-
(2007)
New England Journal of Medicine
, vol.357
, Issue.22
, pp. 2222-2225
-
-
Monath, T.P.1
-
102
-
-
70349576213
-
Recent progress on sanofi pasteurs dengue vaccine candidate
-
Lang J. Recent progress on sanofi pasteur's dengue vaccine candidate. J. Clin. Virol. 46(Suppl. 2), S20-S24 (2009).
-
(2009)
J. Clin. Virol.
, vol.46
, Issue.2
-
-
Lang, J.1
-
103
-
-
40549089216
-
Recombinant chimeric virus with wild-type dengue 4 virus premembrane and envelope and virulent yellow fever virus Asibi backbone sequences is dramatically attenuated in nonhuman primates
-
DOI 10.1086/527329
-
McGee CE, Lewis MG, Claire MS et al. Recombinant chimeric virus with wild-type dengue 4 virus premembrane and envelope and virulent yellow fever virus Asibi backbone sequences is dramatically attenuated in nonhuman primates. J. Infect. Dis. 197(5), 693-697 (2008). (Pubitemid 351364469)
-
(2008)
Journal of Infectious Diseases
, vol.197
, Issue.5
, pp. 693-697
-
-
McGee, C.E.1
Lewis, M.G.2
St. Claire, M.3
Wagner, W.4
Lang, J.5
Guy, B.6
Tsetsarkin, K.7
Higgs, S.8
Decelle, T.9
-
104
-
-
20244371691
-
Yellow fever vaccine: An updated assessment of advanced age as a risk factor for serious adverse events
-
DOI 10.1016/j.vaccine.2005.01.089
-
Khromava AY, Eidex RB, Weld LH et al. Yellow fever vaccine: an updated assessment of advanced age as a risk factor for serious adverse events. Vaccine 23(25), 3256-3263 (2005). (Pubitemid 40523118)
-
(2005)
Vaccine
, vol.23
, Issue.25
, pp. 3256-3263
-
-
Khromava, A.Y.1
Eidex, R.B.2
Weld, L.H.3
Kohl, K.S.4
Bradshaw, R.D.5
Chen, R.T.6
Cetron, M.S.7
Barnett, E.8
Barwick, R.9
Bentsi-Enchill, A.10
Bradshaw, R.D.11
Campbell, S.12
Casey, C.13
Cetron, M.14
Destefano, F.15
Duclos, P.16
Durbin, A.17
English-Bullard, R.18
Feinberg, M.19
Iskander, J.20
Khromava, A.21
Kohl, K.22
Marfin, A.23
Markoff, L.24
McMahon, A.25
Miller, E.26
Montgomery, S.27
Posey, D.28
Russell, M.29
Sejvar, J.30
Shadomy, S.31
Wilson, M.32
Zaki, S.33
Monath, T.34
Teuwen, D.35
more..
-
105
-
-
33745237160
-
Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax™- DEN2) vaccine: Phase I clinical trial for safety and immunogenicity - Effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes
-
Guirakhoo F, Kitchener S, Morrison D et al. Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: Phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes. Hum. Vaccin. 2(2), 60-67 (2006). (Pubitemid 43927159)
-
(2006)
Human Vaccines
, vol.2
, Issue.2
, pp. 60-67
-
-
Guirakhoo, F.1
Kitckener, S.2
Morrison, D.3
Forrat, R.4
McCarthy, K.5
Nichols, R.6
Yoksan, S.7
Duan, X.8
Ermak, T.H.9
Kanesa-Thasan, N.10
Bedford, P.11
Lang, J.12
Quentin-Millet, M.-J.13
Monath, T.P.14
-
106
-
-
77956911340
-
Meningococcal disease in travelers: A rare but devastating disease
-
Wilder-Smith A. Meningococcal disease in travelers: a rare but devastating disease. J. Travel Med. 17(Suppl.), 1-2 (2010).
-
(2010)
J. Travel Med.
, vol.17
, pp. 1-2
-
-
Wilder-Smith, A.1
-
107
-
-
77951646506
-
Review of meningococcal group B vaccines
-
Granoff DM. Review of meningococcal group B vaccines. Clin. Infect. Dis. 50(Suppl. 2), S54-S65 (2010).
-
(2010)
Clin. Infect. Dis.
, vol.50
, Issue.2
-
-
Granoff, D.M.1
-
108
-
-
79958035895
-
Recombinant protein meningococcal serogroup B vaccine combined with outer membrane vesicles
-
Bai X, Findlow J, Borrow R. Recombinant protein meningococcal serogroup B vaccine combined with outer membrane vesicles. Expert Opin. Biol. Ther. 11(7), 969-985 (2011).
-
(2011)
Expert Opin. Biol. Ther.
, vol.11
, Issue.7
, pp. 969-985
-
-
Bai, X.1
Findlow, J.2
Borrow, R.3
-
110
-
-
45949093410
-
Malaria vaccines: A toy for travelers or a tool for eradication?
-
DOI 10.1586/14760584.7.5.597
-
Genton B. Malaria vaccines: a toy for travelers or a tool for eradication? Expert Rev. Vaccines 7(5), 597-611 (2008). (Pubitemid 351890331)
-
(2008)
Expert Review of Vaccines
, vol.7
, Issue.5
, pp. 597-611
-
-
Genton, B.1
-
111
-
-
67650697101
-
Long-term safety and efficacy of the RTS,S/AS02A malaria vaccine in mozambican children
-
Sacarlal J, Aide P, Aponte JJ et al. Long-term safety and efficacy of the RTS,S/AS02A malaria vaccine in Mozambican children. J. Infect. Dis. 200(3), 329-336 (2009).
-
(2009)
J. Infect. Dis.
, vol.200
, Issue.3
, pp. 329-336
-
-
Sacarlal, J.1
Aide, P.2
Aponte, J.J.3
-
112
-
-
57649115306
-
Efficacy of RTS,S/AS01E vaccine against malaria in children 5 to 17 months of age
-
Bejon P, Lusingu J, Olotu A et al. Efficacy of RTS,S/AS01E vaccine against malaria in children 5 to 17 months of age. N. Engl. J. Med. 359(24), 2521-2532 (2008).
-
(2008)
N. Engl. J. Med.
, vol.359
, Issue.24
, pp. 2521-2532
-
-
Bejon, P.1
Lusingu, J.2
Olotu, A.3
-
113
-
-
78650253263
-
Immunogenicity safety and tolerability in adults of a new single-dose live-attenuated vaccine against Japanese encephalitis: Randomised controlled phase 3 trials
-
Torresi J, McCarthy K, Feroldi E, Méric C. Immunogenicity, safety and tolerability in adults of a new single-dose, live-attenuated vaccine against Japanese encephalitis: randomised controlled Phase 3 trials. Vaccine 28(50), 7993-8000 (2010).
-
(2010)
Vaccine
, vol.28
, Issue.50
, pp. 7993-8000
-
-
Torresi, J.1
McCarthy, K.2
Feroldi, E.3
Méric, C.4
-
114
-
-
78751677635
-
Long term immunity to live attenuated Japanese encephalitis chimeric virus vaccine: Randomized double-blind 5-year phase II study in healthy adults
-
Nasveld PE, Ebringer A, Elmes N et al. Long term immunity to live attenuated Japanese encephalitis chimeric virus vaccine: randomized, double-blind, 5-year Phase II study in healthy adults. Hum. Vaccin. 6(12), 1038-1046 (2010).
-
(2010)
Hum. Vaccin.
, vol.6
, Issue.12
, pp. 1038-1046
-
-
Nasveld, P.E.1
Ebringer, A.2
Elmes, N.3
-
115
-
-
67650492061
-
Effective preexposure and postexposure prophylaxis of rabies with a highly attenuated recombinant rabies virus
-
USA
-
Faber M, Li J, Kean RB, Hooper DC, Alugupalli KR, Dietzschold B. Effective preexposure and postexposure prophylaxis of rabies with a highly attenuated recombinant rabies virus. Proc. Natl Acad. Sci. USA 106(27), 11300-11305 (2009).
-
(2009)
Proc. Natl Acad. Sci.
, vol.106
, Issue.27
, pp. 11300-11305
-
-
Faber, M.1
Li, J.2
Kean, R.B.3
Hooper, D.C.4
Alugupalli, K.R.5
Dietzschold, B.6
-
116
-
-
77952322608
-
Inactivated yellow fever 17D vaccine: Development and nonclinical safety immunogenicity and protective activity
-
Monath TP, Lee CK, Julander JG et al. Inactivated yellow fever 17D vaccine: development and nonclinical safety, immunogenicity and protective activity. Vaccine 28(22), 3827-3840 (2010).
-
(2010)
Vaccine
, vol.28
, Issue.22
, pp. 3827-3840
-
-
Monath, T.P.1
Lee, C.K.2
Julander, J.G.3
-
117
-
-
79953785263
-
An inactivated cell-culture vaccine against yellow fever
-
Monath TP, Fowler E, Johnson CT et al. An inactivated cell-culture vaccine against yellow fever. N. Engl. J. Med. 364(14), 1326-1333 (2011).
-
(2011)
N. Engl. J. Med.
, vol.364
, Issue.14
, pp. 1326-1333
-
-
Monath, T.P.1
Fowler, E.2
Johnson, C.T.3
|